is crucial in the diagnosis and staging of preclinical early invasive cervical cancer (International Federation of Gynecology and Obstetrics [FIGO] stages IA1, IA2, and preclinical IB1 lesions).

Eligible patients had high-risk locally advanced cervical cancer, defined as FIGO stage IB2-IIB or FIGO 2014 stage III-IVA disease, regardless of the node status. Patients were randomly assigned ...

for patients with high-risk locally advanced cervical cancer; in other words, those with stage III to IVA disease, according to the FIGO scale. Cervical cancer is on the decline in the US thanks ...

Based on the first interim analysis of the trial, the FDA approved pembrolizumab plus CCRT for the treatment of patients with FIGO 2014 stage III-IVA cervical cancer. KEYNOTE A-18 was a randomized ...

Researchers at AIIMS, Delhi have developed a simple blood test using droplet digital PCR (ddPCR) to track the effectiveness of cervical cancer treatment. Published in Scientific Reports, the study ...

Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival ... 1,060 treatment-naive women with FIGO 2014 stage IB2 to IIB (node-positive disease ...

Most had an ECOG performance score of 0, and most had FIGO (2009 ... the first U.S.-based clinical trial on early-stage high-risk cervical cancer that collected PRO/QoL data prospectively.